<p>Listen as members of Veristat’s regulatory team outline the fundamentals— and the pitfalls— as you determine your readiness to file an Investigational New Drug (IND) from a manufacturing perspective.</p>

Listen as members of Veristat’s regulatory team outline the fundamentals— and the pitfalls— as you determine your readiness to file an Investigational New Drug (IND) from a manufacturing perspective.

CMC Pitfalls: From Benchtop to IND

Cell and gene therapies have made impressive clinical progress but continue to face big hurdles. Nothing is standard about study design, study conduct or regulatory process in this specialized area.

Share CMC Pitfalls: From Benchtop to IND

Sign up to save your podcasts

CMC Pitfalls: From Benchtop to IND

CMC Pitfalls: From Benchtop to IND